Search :
 
Development & market of immunological reagents and kits
SPI-BIO develops, manufactures and markets EIA kits (based on a patented technology) for xenobiotics & biomarkers. This results from a close and long-term co-operation with the French Atomic Energy Commission (CEA) since 1991.
 
Service & Consultant activity
SPI-BIO is also a Drug Development Services Company that proposes scientific expertise and tools for your pharmaceutical research (pre-clinical and clinical phases):
 
 
 
Pharmacology - various investigation fields
 
  • AIDS (HIV), TSE (prions)
  • Vaccines & adjuvants
  • Neuro-degenerative disease (e.g. Immune response in multiple sclerosis)
  • Allergy
  • Inflammation
 
Pharmacokinetics & Metabolism - GLP studies
 
  • Animal & human pharmacokinetics;
  • Intracellular pharmacokinetics;
  • In vivo & in vitro metabolism profile;
  • Alternative in vitro models (human BBB, transporters, CYPs).
 
Bioanalysis for NCEs, peptides, polypeptides & proteins & oligonucleotides
 
  • GLP development, validation of assays & drug measurement;
  • Various techniques such as, HPLC-MS/MS, Immunoassay, competitive hybridization.
 
Microbiological Safety (HIV & prion)
 
  • Assessment of manufacturing & purification processes as wells as detergents & sterilisation steps.
 
Biotransformation Platform for the Generation & Production of NCE & Metabolites
 
     
    SPIbio is one BERTIN GROUP subsidiary. It supplements the Health and Life Science Division which is also composed of 2 other entities ready to shape a project in accordance with Biotech and Pharmaceutical companies' needs:
     
    Innovation & Services in Pharmaceutical Development (Original Drug Delivery Systems, New Products & Processes).
     
    Medical Device and Equipment for Life Science Laboratories & Environment surveillance.